Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system
Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.